Personalis urges stockholders to vote for the Tempus AI merger
The board recommends approval to unlock a 28% premium and combine capabilities for greater market value. The special meeting is on November 30, 2026.
Stay informed with the latest news and media coverage for the biggest companies in Biotechnology & Medical Research. We track all announcements, press releases, and industry mentions in real time, all in one place. Looking for another sector? Browse our industry database.
Last updated
The board recommends approval to unlock a 28% premium and combine capabilities for greater market value. The special meeting is on November 30, 2026.
Order intake increased to SEK 40.8 million while Eva Lindskog was appointed new CEO.
Management will discuss performance and business updates during an earnings call at 4:30 p.m. ET.
Q3 revenue reached $1.13 billion, up 4.2%, driven by NovaSeq X placements and healthy demand.
Unlock all announcements with a free trial
Chemomab Therapeutics Ltd. is an Israel-based biopharmaceutical company that is restructuring its corporate framework through a U.S. domestication. Its operations and assets will be folded...
CLIA certification is a U.S. regulatory requirement for laboratories performing testing on specimens from humans, such as ...
This breakthrough not only turned the code of "think it, do it" into reality, but also marked a crucial step forward for humanity on the...
Orexo AB ( ) just unveiled an announcement. Orexo AB has called an Extraordinary General Meeting for 6 November 2026 in Stockholm, inviting shareholders to...
Unlock all articles with a free trial
Track Every Market Move
Follow your target companies and get daily news updates delivered straight to your inbox
Start free trialBrowse the top companies in Biotechnology & Medical Research and stay on top of their latest developments.